Oncology Medical News about Breast

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial
The American Journal of Surgery, 06/29/09

Nelson JC et al. – Study reports that the locoregional control, complications, and cosmetic outcomes from MammoSite partial breast irradiation (APBI) at the 4-year update are acceptable and similar to results seen with other forms of APBI.

Methods

A 4-year update on the efficacy, cosmetic results, and complications of MammoSite breast brachytherapy in pts enrolled in the American Society of Breast Surgeons registry trial is presented
1,449 breasts in 1,440 pts with early stage BCa undergoing breast-conserving therapy
Pts were treated with adjuvant APBI (34 Gy in 3.4-Gy fractions) delivered with the MammoSite device
Median follow-up period for the entire group was 36.1 months

Results

3-yr actuarial rate of ipsilateral breast tumor recurrence was 2.15%
3-yr actuarial rate of axillary recurrence was 0.36%
Complication rates were: infection, 9.5%; seroma, 26.8%, symptomatic seroma, 12.7%; and fat necrosis, 2.0%
Percentages of breasts with good or excellent cosmetic results were: 12 mo, 95%; 24 mo, 94%; 36 mo, 94%; and 48 mo, 91%

<< Previous
Diffusion-weighted imaging of mucinous carcinoma of the breast

Next >>
Risk factors for positive findings in patients with high-grade T1...